Regulatory News
Thursday, February 2, 2017
BRIEF-Cytomx announces the first patient treated in phase 1/2 proclaim-072 trial
* Cytomx announces the first patient treated in phase 1/2
proclaim-072 trial
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment